Botulinum Toxin A for Idiopathic Toe-walking

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2012

Study Completion Date

April 30, 2012

Conditions
Idiopathic Toe-walking
Interventions
DRUG

Botulinum toxin A

The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.

Trial Locations (1)

Unknown

Astrid Lindren Children's Hospital, Stockholm

All Listed Sponsors
lead

Karolinska Institutet

OTHER

NCT01590693 - Botulinum Toxin A for Idiopathic Toe-walking | Biotech Hunter | Biotech Hunter